MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder

Frontiers in Neurology

Volumn 9, Issue APR, 2018, Pages

  dos Passos, Giordani Rodrigues ^a   Oliveira, Luana Michelli ^b   da Costa, Bruna Klein ^a   Apostolos Pereira, Samira Luisa ^b   Callegaro, Dagoberto ^b   Fujihara, Kazuo ^c   Sato, Douglas Kazutoshi ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Encephalitis; Myelin oligodendrocyte glycoprotein antibody; Myelitis; Neuromyelitis optica spectrum disorder; Optic neuritis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; PREDNISOLONE; RITUXIMAB;

AUTOIMMUNE DISEASE; CELL ASSAY; CELL BASED ASSAY; CEREBROSPINAL FLUID ANALYSIS; DEMOGRAPHY; DISEASE COURSE; ENCEPHALITIS; ENCEPHALOMYELITIS; HUMAN; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MOG IGG ASSOCIATED OPTIC NEURITIS ENCEPHALITIS AND MYELITIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOPHYSIOLOGY; PLASMA EXCHANGE; PREVALENCE; PROGNOSIS; REVIEW;

EID: 85045049538     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2018.00217     Document Type: Review

References (92)

1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 85(2):177-89. doi:10.1212/WNL.0000000000001729
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 364:2106-12. doi:10.1016/S0140-6736(04)17551-X
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 202:473-7. doi:10.1084/jem.20050304
4. Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 80:2194-200. doi:10.1212/WNL.0b013e318296e917
5. Sato DK, Callegaro D, Lana-Peixoto MA, Nakashima I, Fujihara K. Seronegative neuromyelitis optica spectrum-the challenges on disease definition and pathogenesis. Arq Neuropsiquiatr (2014) 72:445-50. doi:10.1590/0004-282X20140032
6. Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 2:e110. doi:10.1212/NXI.0000000000000110
7. Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol (2015) 22(12):e82-3. doi:10.1111/ene.12679
8. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 79:1273-7. doi:10.1212/WNL.0b013e31826aac4e
9. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm (2011) 8:184. doi:10.1186/1742-2094-8-184
10. Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol (2016) 263:1349-60. doi:10.1007/s00415-016-8147-7
11. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm (2016) 13:280. doi:10.1186/s12974-016-0718-0
12. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain (2017) 140:3128-38. doi:10.1093/brain/awx276
13. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry (2018) 89:127-37. doi:10.1136/jnnp-2017-316880
14. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 183:4067-76. doi:10.4049/jimmunol.0801888
15. Brilot F, Dale RC, Selter RC, Grummel V, Reddy Kalluri S, Aslam M, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 66:833-42. doi:10.1002/ana.21916
16. Wang JJ, Jaunmuktane Z, Mummery C, Brandner S, Leary S, Trip SA. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology (2016) 87:229-31. doi:10.1212/WNL.0000000000002844
17. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm (2017) 4:e322. doi:10.1212/NXI.0000000000000322
18. Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry (2017) 88:534-6. doi:10.1136/jnnp-2016-315094
19. Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol (2018) 75:65. doi:10.1001/jamaneurol.2017.3196
20. Fukushima N, Suzuki M, Ogawa R, Hayashi K, Takanashi J, Ohashi T. A case of anti-MOG antibody-positive multiphasic disseminated encephalomyelitis co-occurring with unilateral cerebral cortical encephalitis. Rinsho Shinkeigaku (2017) 57:723-8. doi:10.5692/clinicalneurol.cn-001078
21. Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol (2015) 2:295-301. doi:10.1002/acn3.164
22. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem (1999) 72:1-9. doi:10.1046/j.1471-4159.1999.0720001.x
23. Johns TG, Bernard CC. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol (1997) 34:33-8. doi:10.1016/S0161-5890(97)00005-9
24. Mayer M, Minl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord (2012) 5:147-59. doi:10.1177/1756285611433772
25. Weissert R, Kuhle J, de Graaf KL, Wienhold W, Herrmann MM, Muller C, et al. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J Immunol (2002) 169:548-56. doi:10.4049/jimmunol.169.1.548
26. Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol (2017) 8:529. doi:10.3389/fimmu.2017.00529
27. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T-and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia (2001) 36:220-34. doi:10.1002/glia.1111
28. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, Matthieu JM, et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol (1995) 63:17-27. doi:10.1016/0165-5728(95)00124-7
29. Sakuma H, Kohyama K, Park IK, Miyakoshi A, Tanuma N, Matsumoto Y. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Brain (2004) 127:2201-13. doi:10.1093/brain/awh260
30. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol (1998) 8:681-94. doi:10.1111/j.1750-3639.1998.tb00194.x
31. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 197:1073-81. doi:10.1084/jem.20021603
32. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 116:2393-402. doi:10.1172/JCI28334
33. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 116:2385-92. doi:10.1172/JCI28330
34. Dale RC, Tantsis EM, Merheb V, Kumaran R-YA, Sinmaz N, Pathmanandavel K, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm (2014) 1:e12. doi:10.1212/NXI.0000000000000012
35. Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, Lassmann H, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol (2012) 3:58-73. doi:10.1111/j.1759-1961.2012.00030.x
36. Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler J (2015) 21:656-9. doi:10.1177/1352458514551455
37. Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry (2016) 87(11):1257-9. doi:10.1136/jnnp-2015-312676
38. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm (2015) 2:e62. doi:10.1212/NXI.0000000000000062
39. Zhou L, Huang Y, Li H, Fan J, Zhangbao J, Yu H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol (2017) 305:19-28. doi:10.1016/j.jneuroim.2017.01.007
40. Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze H-J, Matzke M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: two case reports. Neurol Neuroimmunol Neuroinflamm (2017) 4:e335. doi:10.1212/NXI.0000000000000335
41. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler J (2016) 22:1541-9. doi:10.1177/1352458515622986
42. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 47:707-17. doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
43. Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, et al. Fulminant demyelinating encephalomyelitis. Neurol Neuroimmunol Neuroinflamm (2015) 2:e175. doi:10.1212/NXI.0000000000000175
44. Brehm U, Piddlesden SJ, Gardinier MV, Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol (1999) 97:9-15. doi:10.1016/S0165-5728(99)00010-7
45. von Büdingen H-C, Hauser SL, Ouallet J-C, Tanuma N, Menge T, Genain CP. Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol (2004) 34:2072-83. doi:10.1002/eji.200425050
46. O'Connor KC, Mclaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 13:211-7. doi:10.1038/nm1488
47. Spadaro M, Meinl E. Detection of autoantibodies against myelin oligodendrocyte glycoprotein in multiple sclerosis and related diseases. Methods Mol Biol (2015) 1304:99-104. doi:10.1007/7651_2015_223
48. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, De Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 82:474-81. doi:10.1212/WNL.0000000000000101
49. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol (2014) 71:1-8. doi:10.1001/jamaneurol.2013.5857
50. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 21(7):866-74. doi:10.1177/1352458514555785
51. van Pelt ED, Wong YYM, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol (2015) 23(3):580-7. doi:10.1111/ene.12898
52. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol (2012) 69:752-6. doi:10.1001/archneurol.2011.2956
53. Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler (2013) 19:1052-9. doi:10.1177/1352458512470310
54. Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2014) 1:e40. doi:10.1212/NXI.0000000000000040
55. Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2015) 2:e131-131. doi:10.1212/NXI.0000000000000131
56. Cobo-Calvo á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler (2015) 22:312-9. doi:10.1177/1352458515591071
57. Hyun J-W, Kim S-H, Huh S-Y, Kim W, Yun J, Joung A, et al. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Mult Scler (2015) 21:710-7. doi:10.1177/1352458514551454
58. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm (2015) 2:e163-163. doi:10.1212/NXI.0000000000000163
59. Pröbstel A-K, Rudolf G, Dornmair K, Collongues N, Chanson J-B, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm (2015) 12:1-7. doi:10.1186/s12974-015-0256-1
60. Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Mult Scler J (2015) 22(7):964-8. doi:10.1177/1352458515614093
61. Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci (2016) 59:1270-81. doi:10.1007/s11427-015-4997-y
62. Woodhall M, çoban A, Waters P, Ekizoglu E, Kürtüncü M, Shugaiv E, et al. Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci (2013) 335:221-3. doi:10.1016/j.jns.2013.08.034
63. Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 2:e134. doi:10.1212/NXI.0000000000000134
64. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J (2015) 21:845-53. doi:10.1177/1352458515572406
65. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement-frequency, presentation and outcome. J Neuroinflamm (2016) 13:281. doi:10.1186/s12974-016-0719-z
66. Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 3:e257. doi:10.1212/NXI.0000000000000257
67. Amano H, Miyamoto N, Shimura H, Sato D, Fujihara K, Ueno S, et al. Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. BMC Neurol (2014) 14:224. doi:10.1186/s12883-014-0224-x
68. Nakamura Y, Nakajima H, Tani H, Hosokawa T, Ishida S, Kimura F, et al. Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol (2017) 17:76. doi:10.1186/s12883-017-0858-6
69. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflamm (2016) 13:279. doi:10.1186/s12974-016-0717-1
70. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 77:580-8. doi:10.1212/WNL.0b013e318228c0b1
71. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler (2015) 22(4):470-82. doi:10.1177/1352458515593406
72. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry (2016) 87:446-8. doi:10.1136/jnnp-2014-310206
73. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm (2016) 13:282. doi:10.1186/s12974-016-0720-6
74. Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, et al. Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One (2017) 12:e0170847. doi:10.1371/journal.pone.0170847
75. Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders. Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm (2016) 3:e225. doi:10.1212/NXI.0000000000000225
76. Baumann M, Hennes E-M, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler (2016) 22(14):1821-9. doi:10.1177/1352458516631038
77. Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm (2015) 2:e81. doi:10.1212/NXI.0000000000000081
78. Ketelslegers IA, Van Pelt DE, Bryde S, Neuteboom RF, Catsman-Berrevoets CE, Hamann D, et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler J (2015) 4:1-8. doi:10.1177/1352458514566666
79. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler J (2015) 22:174-84. doi:10.1177/1352458515587751
80. Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol (2011) 138:247-54. doi:10.1016/j.clim.2010.11.013
81. Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostásy K, Berger T, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 191:3594-604. doi:10.4049/jimmunol.1301296
82. Oshiro A, Nakamura S, Tamashiro K, Fujihara K. [Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis]. No To Hattatsu (2016) 48:199-203. doi:10.11251/ojjscn.48.199
83. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 10:493-506. doi:10.1038/nrneurol.2014.141
84. Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open (2015) 5:e007766-007766. doi:10.1136/bmjopen-2015-007766
85. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int (2012) 2012:1-9. doi:10.1155/2012/787630
86. Nozaki I. Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry (2006) 77:1094-5. doi:10.1136/jnnp.2005.086306
87. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology (2010) 75:1423-7. doi:10.1212/WNL.0b013e3181f8832e
88. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler (2012) 18:1480-3. doi:10.1177/1352458512439439
89. Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler (2012) 18:108-12. doi:10.1177/1352458511421185
90. Kitley J, Evangelou N, Küker W, Jacob A, Leite MI, Palace J. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci (2014) 339:223-5. doi:10.1016/j.jns.2014.01.035
91. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler (2012) 18:113-5. doi:10.1177/1352458511431973
92. Izaki S, Narukawa S, Kubota A, Mitsui T, Fukaura H, Nomura K. [A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment]. Clin Neurol (2013) 53:513-7. doi:10.5692/clinicalneurol.53.513